Pulmonary surfactant: Functions, abnormalities and therapeutic options

Intensive Care Medicine

Volumn 27, Issue 11, 2001, Pages 1699-1717

  Frerking, Ilka ^a   Günther, Andreas ^b   Seeger, Werner ^b   Pison, Ulrich ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; AUTACOID; COLLECTIN; CYTOKINE; ELASTASE; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; KL 4; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; LUSUPULTIDE; PHOSPHOLIPID; RESPIRATORY TRACT AGENT; SURFACTANT PROTEIN A; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBACTERIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ASTHMA; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIARY MOTILITY; CLINICAL TRIAL; CYTOKINE RELEASE; EMPHYSEMA; GAS EXCHANGE; HOST RESISTANCE; HUMAN; LUNG ALVEOLUS SURFACE TENSION; LUNG MECHANICS; LUNG PRESSURE; LUNG VOLUME; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PILOT STUDY; PNEUMONIA; REVIEW; TREATMENT OUTCOME;

ADULT; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LUNG DISEASES; PULMONARY GAS EXCHANGE; PULMONARY SURFACTANTS; RESPIRATORY MECHANICS;

EID: 0035206189     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-001-1121-5     Document Type: Review

References (216)

1. Effect of surfactant on morbidity, mortality and resource use in newborn infants weighing 500 to 1500 g
2. Neue Auffassungen über einen Grundbegriff der Atemmechanik; die Retraktionskraft der Lunge, abhängig von der Oberflächenspannung in den Alveolen
3. Properties, function and origin of the alveolar lining layer
4. Surface tension of lung extracts
5. Pulmonary surfactant
6. Isolation and chemical composition of pulmonary surfactant
7. Phosphatidylcholine molecular species of calf lung surfactant
8. Conductive airway surfactant: Surface-tension function, biochemical composition and possible airway origin
9. Pulmonary and gastric surfactants. A comparison of the effect of surface requirements on function and phospholipid composition
10. A proposed nomenclature of pulmonary surfactant-associated proteins
11. Purification and biochemical characterization of CP4 (SP-D): A collagenous surfactant-associated protein
12. Surfactant: A review of its functions and relevance in respiratory disorders
13. Hydrophobic surfactant proteins SP-B and SP-C: Molecular biology, structure and function
14. Pulmonary surfactant: A surface chemistry viewpoint
15. Composition of surface-active material isolated from beef lungs
16. The surfactant system of the adult lung: Physiology and clinical perspectives
17. Pulmonary dysfunction in neonatal SP-B-deficient mice
18. Altered stability of pulmonary surfactant in SP-C deficient mice
19. Clinical trials of surfactant therapy in the newborn
20. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome
21. Surfactant in neonatal RDS
22. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants
23. Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury
24. Aerosolized surfactant improves gas exchange in detergent treated, isolated rabbit lungs
25. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome
26. Prevention of neonatal distress syndrome by tracheal instillation of surfactant: A randomized clinical trial
27. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis
28. Host defense capacities of pulmonary surfactant: Evidence for "non-surfactant" functions of the surfactant system
29. Alveolar lining layer is thin and continous: Low-temperature scanning electron microscopy of rat lung
30. Formation and structure of surface films: Captive bubble surfactometry
31. Role of pulmonary surfactant components in surface film formation and dynamics
32. Interactions of surfactant protein A with pathogens
33. The mucociliary system of the lung - Role of surfactant
34. Exogenous surfactant enhances mucociliary clearance in the anesthetized dog
35. Effect of artificial surfactant on ciliary beat frequency in guinea pig trachea
36. Effects of bovine surfactant (bLES) on rheological properties and mucociliary transport of respiratory secretions in cystic fibrosis (CF) patients
37. Effect of surfactant on bioelectric properties of canine tracheal epithelium
38. Airway surfactant, a primary defense barrier: Mechanical and immunological aspects
39. Inhibition of the human neutrophil respiratory burst by native and synthetic surfactant
40. Synthetic surfactant scavenges oxidants and protects against hyperoxic lung injury
41. Natural surfactant and hyperoxic lung injury in primates. 2. Morphometric analysis
42. Type II pneumocytes secrete vitamin E together with surfactant lipids
43. Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury
44. Natural surfactant and hyperoxic lung injury in primates. I. Physiology and biochemistry
45. Artificial surfactant attenuates hyperoxic lung injury in primates. I. Physiology and biochemistry
46. Artificial surfactant attenuates hyperoxic lung injury in primates. II. Morphometric analysis
47. Tyloxapol confers durable protection against hyperoxic lung injury in the rat
48. Role of surfactant free fatty acids in antimicrobial defenses
49. Human alveolar lining material and antibacterial defences
50. Interactions of surfactant protein A with influenza A viruses: Binding and neutralization
51. Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages
52. Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses
53. Mechanisms of binding of surfactant protein D to influenza A viruses: Importance of binding to haemagglutinin to antiviral activity
54. Collectins: Collagenous C-type lectins of the innate immune defense system
55. Collectins and pulmonary innate immunity
56. Collectin structure: A review
57. Collectins and pulmonary host defense
58. Developmental expression of SP-A and SP-A mRNA in the proximal and distal respiratory epithelium in the human fetus and newborn
59. Immunomodulatory functions of surfactant
60. Functional roles of the lung surfactant protcins SP-A and SP-D in innate immunity
61. Specific binding of surfactant apoprotein SP-A to alveolar macrophages
62. Specific interaction of lung surfactant protein A (SP-A) with rat alveolar macrophages
63. Interactions of surfactant protein A with epithelial cells and phagocytes
64. Human leukocyte Clq receptor binds to other soluble proteins with collagen domains
65. Interaction of Clq, and other proteins containing collagen-like domains, with the Clq receptor
66. Clq: Structure, function and receptors
67. Complement-mediated host defense in the lung
68. A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and Clq B chain globular domain, is an inhibitor of the classical complement pathway
69. Modular organization of carbohydrate recognition domains in animal lectins
70. Modular organization of proteins containing Clq-like globular domains
71. Pulmonary surfactant protein A stimulates chemotaxis of alveolar macrophages
72. Pulmonary surfactant protein A enhances the host defense mechanism of rat alveolar macrophages
73. The pulmonary surfactant system: Biochemical and clinical aspects
74. Surfactant protein A enhances the binding and deacylation of E. coli LPS by alveolar macrophages
75. Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite
76. Surfactant protein A enhances mycobacterial killing by rat macrophages through a nitric oxide-dependent pathway
77. Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages
78. Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages
79. Surfactant protein D binding to alveolar macrophages
80. Role of pulmonary surfactant protein D in innate defense against Candida albicans
81. Localisation of lung surfactant protein D on mucosal surfaces in human tissues
82. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria
83. Surfactant associated protein A inhibits human lymphocyte proliferation and IL-2 production
84. Recombinant rat surfactant-associated protein D inhibits human T lyphocyte proliferation and IL-2 production
85. Artificial surfactant (Surfactant TA) modulates adherence and superoxide production of neutrophils
86. Surfactant protein A stimulation of inflammatory cytokine and immunoglobulin production
87. Surfactant protein A regulates cytokine production in the monocytic cell line THP-1
88. Surfactant protein A protects growing cells and reduces TNF-alpha activity from LPS-stimulated macrophages
89. Effect of surfactant protein A (SP-A) on the production of cytokines by human pulmonary macrophages
90. Surfacatnt protein D modulates interaction of Pneumocystis carinii with alveolar macrophages
91. Human SP-A protein variants derived from one or both genes stimulate TNF-alpha production in the THP-1 cell line
92. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection
93. Distinct effects of surfactant protein A or D deficiency during bacterial infection of the lung
94. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo
95. SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection
96. Surfactant protein-A binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice
97. Which surfactant for treatment of respiratory-distress syndrome
98. Lung development and function in preterm infants in the surfactant treatment era
99. Surface tension as a factor in the resistance of neonatal lungs to aeration
100. Surface properties in relation to atelectasis and hyaline membrane disease
101. Artificial surfactant therapy in hyaline-membrane disease
102. Systematic review of prophylactic vs rescue surfactant
103. Mortality, severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf
104. Comparison of prophylaxis and rescue therapy with Curosurfr in neonates less than 30 weeks' gestation: A randomized trial
105. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation
106. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates 29 through 32 weeks gestation
107. Overview of clinical trials comparing natural and synthetic surfactants
108. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome
109. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs
110. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome
111. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: A randomised trial
112. Effects of lung surfactant factor (LSF) treatment on gas exchange and histopathological changes in an animal model of adult respiratory distress syndrome (ARDS): Comparison of recombinant LSF with bovine LSF
113. Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS)
114. Comparison of rSP-C surfactant with natural and synthetic surfactants after late treatment in a rat model of the acute respiratory distress syndrome
115. Effects of rSP-C surfactant on oxygenation and lung injury in a rat-lung-lavage model of acute lung injury
116. Effect of recombinant SP-S surfactant in a porcine lavage model of acute lung injury
117. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome
118. Bronchopulmonary segmental lavage with Surfaxin (KL4-Surfactant) for acute respiratory distress syndrome
119. Principles of surfactant replacement
120. Lung surfactant phospholipids associate with polymerizing fibrin: Loss of surface activity
121. Surfactant abnormalities and adult respiratory failure
122. Proteolytic cleavage of fibrinogen: Amplification of its surfactant inhibitory capacity
123. Alteration of surfactant function due to protein leakage: Special interaction with the fibrin monomer
124. In vivo cvaluation of the inhibitory capacity of human plasma on exogenous surfactant function
125. Effect of fibrinogen degradation products and lung ground substance on surfactant function
126. Early versus delayed neonatal administration of synthetic surfactant
127. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: An autopsy evaluation
128. Survival, cranial ultrasound and cerebral palsy in very low birth weight infants: 1980s versus 1990s
129. Health and developmental outcomes of a surfactant controlled trial: Follow-up at 2 years
130. Pulmonary surfactant therapy
131. Annual summary of vital statistics - 1990
132. Acute respiratory distress in adults
133. The adult respiratory syndrome: Clinical features, factors influencing prognosis and principles of management
134. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes and clinical trial coordination
135. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome and cardiogenic lung edema
136. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome
137. Evidence of lung surfactant abnormality in respiratory failure
138. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome
139. Surfactant abnormalities in patients with respiratory failure after multiple trauma
140. Compositional, structural and functional alterations in pulmonary surfactant in surgical patients after the early onset of systemic inflammatory response syndrome or sepsis
141. Alteration of fatty acid profile in different surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia
142. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS
143. Surfactant subtype conversion is related to loss of surfactant apoprotein B and surface activity in large surfactant aggregates
144. Pulmonary surfactant subfractions in patients with acute respiratory distress syndrome
145. Alveolar fibrin formation caused by cnhanccd procoagulant and dcprcsscd fibrinolytic capacities in severe pneumonia - Comparison with the acute respiratory distress syndrome
146. Proteolytic inactivation of dog lung surfactant-associated proteins by neutrophil elastase
147. Damage to surfactant-specific protein in acute respiratory distress syndrome
148. Increased levels of nitrate and surfactant protein A nitration in the pulmonary edema fluid of patients with acute lung injury
149. Nitric oxide and nitrotyrosine in the lungs of patients with acute repiratory distress syndrome
150. Is NO news bad in acute respiratory distress syndrome?
151. Aerolized surfactant in adults with sepis-induced acute respiratory distress syndrome
152. Bovine surfactant therapy for patients with acute respiratory distress syndrome
153. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome
154. Treatment of ARDS with rSP-C surfactant
155. Safcty and potential efficacy of an aerolized surfactant in human sepsis-induced adult respiratory distress syndrome
156. Surfactant inhibition by plasma proteins: Differential sensitivity of various surfactant preparations
157. Efficacy of inhaled nitric oxide in patients with severe ARDS
158. Effect of inhaled nitric oxide in combination with almitrine on ventilationperfusion distributions in experimental lung injury
159. Prostacyclin enhances stretch-induced surfactant secretion in alveolar epithelial type II cells
160. Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation
161. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome
162. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure
163. Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and adult respiratory distress syndrome
164. Decreased surfactant protein A in patients with bacterial pneumonia
165. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia
166. Increased recovery of surfactant protein A in AIDS-related pneumonia
167. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice
168. Exacerbation of influenzavirus pneumonia by intranasal administration of surfactant in a mouse model
169. Selective intrabronchial instillation of surfactant in a patient with pneumonia: A preliminary report
170. Surfactant therapy in severe neonatal respiratory failure - Multicenter study - III. Surfactant therapy in 41 premature infants under 34 weeks with suspected congenital infection (case-control analysis)
171. Influence of natural or synthetic surfactant preparations on the growth bacteria causing infections in the neonatal period
172. Differential leukocyte count in babies treated with natural surfactant
173. Immunogenicity and immunomodulatory activity of bovine surfactant (SF-RI 1)
174. Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with survanta, a modified bovine surfactant
175. Mast cells as a source of multifunctional cytokines
176. Inflammatory mediators involved in antigen-induced airway microvascular leakage in guinea pigs
177. Pulmonary surfactant suppresses the immune lung injury response to inhaled antigen in guinea pigs
178. Pulmonary surfactant given prophylactically alleviates an asthma attack in guinea-pigs
179. Surfactant function affected by airway inflammation and cooling: Possible impact on exercise-induced asthma
180. Surface activity of sputum from acute asthmatic patients
181. A pilot study of surfactant inhalation for the treatment of asthma attack
182. Dysfunction of pulmonary surfactant in asthmatics after allergen challenge
183. Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant
184. Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma
185. A1tered airway surfactant phospholipid composition and reduced lung function in asthma
186. Surfactant protein A in bronchoalveolar lavage fluid
187. Pollen grains bind to alveolar type II cells (A459) via lung surfactant protein A (SP-A)
188. Interaction of human lung surfactant protein A and D with mite (Dermatophagoides pteronyssinus) allergens
189. Inhibitory effect of pulmonary surfactant proteins A and D on allergen-induced lymphocyte proliferation and histamine release in children with asthma
190. IL-5 mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice
191. Differential susceptibility to tobacco smoke: Possible mechanisms
192. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: Definitions, epidemiology, pathophysiology, diagnosis and staging
193. Emphysema: The first two centuries-and beyond. A historical overview, with suggestions for future research. Part 1
194. Emphysema: The first two centuries-and beyond. A historical overview, with suggestions for future research. Part 2
195. Pathological changes in the peripheral airways of young cigarette smokers
196. Relationship of alveolar macrophage plasminogen activator and elastase activities to lung function and CT evidence of emphysema
197. Alterations in stress distributions around alveolar pores after exposure to papain in dogs
198. Effect of smoking on the lipid composition of lung lining fluid and relationship between immunostimulatory lipids, inflammatory cells and foamy macrophages in extrinsic allergic alveolitis
199. Effects of cigarette smoke and plant smoke on pulmonary surfactant
200. Surfactant in chronic smokers
201. Low yield of pulmonary surfactant in cigarette smokers
202. Biochemical analyses of bronchoalveolar lavage fluids of healthy human volunteer smokers and nonsmokers
203. Lack of type II cells and emphysema in human lungs
204. Augmentation of elastase-induced emphysema by cigarette smoke. Effects of reduced nicotine content
205. Protective effect of pulmonary surfactant on elastase-induced emphysema in mice
206. Neltenexine: Morphological investigations of protection against elastase-induced emphysema in rats
207. Effects of activated polymorphonuclear leukocytes upon pulmonary surfactant in vitro
208. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers
209. Spontanous emphysema in surfactant protein D gene-targeted mice
210. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D
211. Surfactant protein D regulates surfactant phospholipid homeostasis in vivo
212. Increased metalloproteinase activity, oxidant production and emphysema in surfactant protein D gene-inactivated mice
213. Polymorphisms of surfactant protein gene A, B, D, and of SP-B linked microsattelite markers in COPD of a Mexican population
214. Platelet-activating factor in surfactant preparations
215. Plateletactivting factor (PAF)-acetylhydrolase and PAF-like compounds in the lung: Effects of hyperoxia
216. Porcine pulmonary surfactant preparations contain the antibacterial peptide prophenin and a Cterminal 18-residue fragment thereof